Skip to main content

Easy guide for Down’s syndrome, Edwards’ syndrome and Patau’s syndrome screening updated thanks to expert users

Posted by: , Posted on: - Categories: NHS Fetal Anomaly Screening Programme

Updated easy guide published that explains NHS screening for Down’s syndrome, Edwards’ syndrome and Patau’s syndrome, including information about non-invasive prenatal testing (NIPT).

NIPT rolls out to all areas of England as part of the existing NHS screening pathway for Down’s syndrome, Edwards’ syndrome and Patau’s syndrome

Posted by: , Posted on: - Categories: NHS Fetal Anomaly Screening Programme

All maternity providers across England are now offering non-invasive prenatal testing (NIPT) as part of the existing NHS screening pathway for Down’s syndrome, Edwards’ syndrome and Patau’s syndrome.

Lay members wanted for antenatal and newborn screening programmes research advisory committee

The research advisory committee (RAC) reviews applications to carry out research involving NHS screening programme participants or requiring access to screening data or samples.

Thank you, thank you, thank you – what you do makes a difference

We (PHE Screening, and NHS England and NHS Improvement) want to take a moment to recognise the huge contribution of all staff who work so hard to deliver the NHS antenatal and newborn screening programmes.

NIPT to be evaluated as a new part of NHS screening pathway for Down’s syndrome, Edwards’ syndrome and Patau’s syndrome

Posted by: , Posted on: - Categories: NHS Fetal Anomaly Screening Programme

Non-invasive prenatal testing (NIPT) was today added to the existing NHS screening pathway for Down’s syndrome, Edwards’ syndrome and Patau’s syndrome.

New operational guidance for NIPT screening within the NHS

Posted by: , Posted on: - Categories: NHS Fetal Anomaly Screening Programme

PHE Screening has today published new operational guidance on non-invasive prenatal testing (NIPT), which will be added to the existing NHS screening programme for Down's syndrome, Edwards' syndrome and Patau's syndrome as part of an evaluative rollout from 1 June 2021.